Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes

Rheumatology

Volumn 49, Issue 8, 2010, Pages 1466-1471

  Dickie, Laura J ^a   Church, Leigh D ^b   Coulthard, Lydia R ^a   Mathews, Rebeccah J ^a   Emery, Paul ^a   McDermott, Michael F ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

IL 6; Systemic lupus erythematosus; TLR9; Toll like receptors; Vitamin D3

Indexed keywords

CD14 ANTIGEN; COLECALCIFEROL; INTERLEUKIN 6; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; AUTOIMMUNE DISEASE; CELL CULTURE; IMMUNOLOGY; METABOLISM; STATISTICS; TIME;

AUTOIMMUNE DISEASES; CELLS, CULTURED; CHOLECALCIFEROL; DOWN-REGULATION; HUMANS; INTERLEUKIN-6; MONOCYTES; STATISTICS AS TOPIC; TIME FACTORS; TOLL-LIKE RECEPTOR 9;

EID: 77954703735     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq124     Document Type: Article

References (25)

1. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev 2007;7:79-90.
2. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13:52-9.
3. Papadimitraki ED, Choulaki C, Koutala E et al. Expansion of Toll-like receptor 9-expressing B cells in active sys-temic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006;54:3601-11.
4. Lartigue A, Courville P, Auquit I et al. Role of TLR9 in anti-nucleosome and anti-DNA antibody production in LPR mutation-induced murine lupus. J Immunol 2006;177:49-54.
5. Durakovic C, Ray S, Holick MF. Topical paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study. Br J Dermatol 2004;151:90-5.
6. Flanagan JN, Zheng S, Chiang KC et al. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res 2009;29:47-53.
7. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev 2008;8:685-98.
8. Jeffery LE, Burke F, Mura M et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009;183:58-67.
9. Sadeghi K, Wessner B, Laggner U et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol 2006;36:61-70.
10. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000;164:2405-11.
11. Xu H, Soruri A, Gieseler RK, Peters JH. 1,25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity and phagocytosis of human monocytes. Scand J Immunol 1993;38:35-40.
12. Yuk JM, Shin DM, Lee HM et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009;6:31-43.
13. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2004;50:72-7.
14. Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004;80(Suppl. 6):7S-20S.
15. Lemire JM, Ince A, Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity 1992;12:43-8.
16. Borba VZ, Vieira JG, Kasamatsu T, Radominski SC, Sato EI, Lazaretti-Castro M. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int 2009;20:27-33.
17. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001;358:1500-3.
18. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006;5:114-7.
19. Souza HN, Lora FL, Kulak CA, Manas NC, Amarante HM, Borba VZ. Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density. Arq Bras Endocrinol Metabol 2008;52:84-91.
20. 3 in human monocytes systematic review and meta-analysis. Arch Dis Child 2008;93:512-7.
21. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998;128:68-72.
22. Du T, Zhou ZG, You S et al. Regulation by 1, 25-dihydroxy-vitamin D3 on altered TLRs expression and response to ligands of monocyte from autoimmune diabetes. Clin Chim Acta 2009;402:33-8.
23. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract 2007;77:47-57.
24. Mellor-Pita S, Citores MJ, Castejon R et al. Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin 10 in systemic lupus erythematosus. Cytometry B Clin Cytom 2009;76B:61-70.
25. Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006;119:296-305.